Authors


Sai Ma, PhD

Latest:

Insurers’ Perspectives on MA Value-Based Insurance Design Model

This article describes perspectives of Medicare Advantage (MA) insurers about participating in the CMS value-based insurance design model test launched in 2017.


David Newman, JD, PhD

Latest:

Overcoming Barriers to a Research-Ready National Commercial Claims Database

Lessons learned about data governance and distribution from a voluntary healthcare claims repository, the Health Care Cost Institute, a nonprofit research organization


Marlon P. Mundt, PhD

Latest:

Putting the Pieces Together: EHR Communication and Diabetes Patient Outcomes

More frequent electronic health record (EHR) message forwarding in primary care teams is associated with worse outcomes and higher medical costs for patients with diabetes.


Stefan Vegter, PharmD

Latest:

Compliance, Persistence, and Switching Patterns for ACE Inhibitors and ARBs

This drug-utilization study in a prescription database of more than 50,000 patients analyzed compliance, persistence, and switching behavior for ACE inhibitors and ARBs.



Dan Patrick

Latest:

A Medicare Appeal for CGM Coverage: One Patient's Never-Ending Story

The author, who has lived with type 1 diabetes for more than 50 years, shares his account of a successful appeal of Medicare's policy of refusing to pay for continuous glucose monitoring (CGM).



Avivit Golan-Cohen, MD

Latest:

Changing Electronic Formats Is Associated With Changes in Number of Laboratory Tests Ordered

A slight decrease in the convenience of ordering a laboratory test led to a dramatic decrease in test utilization.




Jonathan T. Caranfa, PharmD

Latest:

Humanistic and Economic Burden of Hepatocellular Carcinoma: Systematic Literature Review

Worldwide, more than half a million new cases of hepatocellular carcinoma (HCC) are diagnosed annually. The incidence of HCC in the United States is rising with an estimated 31,000 new cases in 2018. Disease prognosis remains poor, with a 5-year survival rate across all disease stages estimated between 10%-20%, and 3% for those diagnosed with distant disease. Although morbidity is significant, especially among patients with advanced-stage disease, limited information exists on the humanistic and economic burden of HCC.


Oscar A. Wehmanen, MS

Latest:

Improving Influenza Immunization in Pregnant Women and Healthcare Workers

Influenza vaccination rates in pregnant women and healthcare workers were increased with standing orders, vaccine advocates, and educational activities on influenza immunization.




Brennan Spiegel, MD, MSHS

Latest:

Cost-Effectiveness of Pharmacist Postdischarge Follow-Up to Prevent Medication-Related Admissions

A multivariable sensitivity analysis conducted on a pharmacy follow-up program of high-risk patients demonstrated cost savings to hospitals in 98.3% of head-to-head trials across 1000 hypothetical hospitals.


Melissa Hamilton, MPH

Latest:

Oral Anticoagulant Discontinuation in Patients With Nonvalvular Atrial Fibrillation

The risk of discontinuation of oral anticoagulant therapy (both warfarin and direct oral anticoagulant therapies [DOACs]) among nonvalvular atrial fibrillation patients was high. Although the hazard ratio for discontinuation favors DOACs, it is unlikely that the small difference in discontinuation relative to warfarin is clinically meaningful.



Todd J. Osbeck, MM

Latest:

Health Plan Use of Immunization Information Systems for Quality Measurement

Health plans may benefit from using a state immunization information system as the primary data source for HEDIS and physician incentive and quality programs.


David S. Zingmond, MD, PhD

Latest:

Targeting a High-Risk Group for Fall Prevention: Strategies for Health Plans

This study evaluates different strategies to identify high fall risk among community-dwelling elders using a combination of easily obtainable administrative data and patient screening questions.


Bert R. Meijboom, PhD

Latest:

Accountable Care Organizations: How to Dress for Success

Accountable care organizations will be more successful in taking on accountability for patient outcomes when market and firm organization get a balanced treatment.



Phuoc Anh (Anne) Nguyen, PharmD, MS, BCPS

Latest:

Pharmacy Team Engagement in Navigating the Revenue Cycle for High-Cost Medications in Patients With Cancer

With the clinical and financial implications of high-cost medications, and their impact on health system revenue, it is of utmost importance for all key stakeholders to be engaged in the complex revenue cycle.



Verghese T. Cherian, MD

Latest:

Patients’ Expectations of Their Anesthesiologists

Understanding patients’ expectations, educating them about the role of an anesthesiologist, and involving them in decisions about their medical care can improve patient satisfaction.



Sean M. Devlin, MA

Latest:

Complementary and Alternative Medicine Provider Use and Expenditures by Cancer Treatment Phase

More than 26% of cancer patients see CAM providers, primarily for musculoskeletal problems; use does not vary by treatment phase, and associated expenditures are low.




Jeffrey C. Schneider, MD

Latest:

Functional Status and Readmissions in Unilateral Hip Fractures

Functional status is an important predictor of an acute care readmission in patients who have had a unilateral hip fracture.


Michael Genau, MS

Latest:

Safety Net Representation in Federal Payment and Care Delivery Reform Initiatives

Although safety net organizations are eligible for some two-thirds of federal payment reform programs, fewer than 20% of these programs directly target the safety net.

AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo